Deltex Medical Group – Investors

During surgery, good perfusion is critical for optimal patient outcomes. Poor perfusion leads to poor clinical outcomes, increased post-operative complications and more unwell patients – leading to extended length of stay in hospital and thus increased costs. Conversely, good cardiac output gives rise to good perfusion – hence healthy organs and improved clinical outcomes – as well as reduced post-operative complications. Cardiac output is key.

Deltex Medical Group plc (“DEMG”) pioneered oesophageal Doppler monitoring (“ODM”) technology which measures cardiac output from central blood flow. This ODM technology is now available via its recently launched TrueVue monitor and its ODM probes. This provides highly accurate, real time, beat-to-beat cardiac output data. Improved patient outcomes and shorter length of stay using protocols guided by Deltex Medical’s technology is supported by some 24 academic studies.

Deltex Medical’s ‘flow’ based, real time cardiac output monitoring is typically used for patients undergoing moderate- to high-risk surgical procedures where there is a high risk of blood loss and instability. Examples include: emergency laparotomies; transplants; gynaecological oncology; and colorectal surgery where accurate assessment and management of a patient’s cardiac output is an important element of ensuring successful patient outcomes.

DEMG is developing its business in the UK and overseas, working with its network of international distributors, by focusing on the sale of its new TrueVue monitor – and the associated ODM probes – for use with these high-risk procedures, emphasising improving patient outcomes – and reduced healthcare system costs. DEMG is also working on obtaining 510(k) approval for the key US market, as well as developing complementary non-invasive haemodynamic monitoring technology.